Nuevolution AB (publ)

NUE

SE0007730650

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets			5-day change	1st Jan Change
- ^SEK	-.--%		-0.31%	+90.59%

2019	Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.	CI
2019	Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019	CI

Nuevolution A/S Appoints Zambrowicz as Director and Senior Scientific Advisor to the Board of Directors

May 20, 2014

Nuevolution A/S announced that Dr. Brian Zambrowicz, Ph.D has joined Nuevolution as Director and Senior Scientific Advisor to the Board of Directors. Brian Zambrowicz, Ph.D. is one of the co-founders of Lexicon Pharmaceuticals Inc. and has served the company as Executive Vice President and Chief Scientific Officer since 2007.

Latest news about Nuevolution AB (publ)

Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.	19-07-03	CI
Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019	19-05-22	CI
Amgen Inc. made an offer to acquire Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others for SEK 1.6 billion.	19-05-20	CI
Nuevolution's BET-BD1 Selective Inhibitor and Candidate Compound, NUE20798, Shows Positive Effect on Disease Scoring and Biomarker Levels in an Atopic Dermatitis Mouse Model	19-05-09	CI
Nuevolution AB Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018	19-04-04	CI
Nuevolution AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	19-02-28	CI
Nuevolution AB Announces First Animal Preclinical Data	19-02-21	CI
Nuevolution AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-27	CI
Nuevolution to Present Data from its Discovery Program Directed at Targeting the Key Disease Inflammatory Signaling Molecule, Interleukin-17A (IL-17A)	18-10-11	CI
Nuevolution AB Announces Executive Changes	18-08-31	CI
Nuevolution AB Announces Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-22	CI
Nuevolution Discloses the Identity of Its Cytokine X Program Being Interleukin IL-17A	18-08-22	CI
Amgen Exercises Opt-In Right in First Program from Multiple Target Research Collaboration with Nuevolution	18-07-18	CI
Nuevolution AB(OM:NUE) added to OMX Nordic Small Cap Index	18-07-10	CI
Nuevolution AB(OM:NUE) added to OMX Nordic All-Share Index	18-07-09	CI
Nuevolution AB Announces Unaudited Group and Parent Earnings Results for the First Quarter Ended March 31, 2018	18-05-08	CI
Nuevolution AB Obtains New Data in its Internal RORt Program Supporting Effect in Human Inflammatory Bowel Diseases	18-04-26	CI
Fredrik Arp Not to Stand for Re-Election as Director of Nuevolution AB	18-04-24	CI
Nuevolution AB Announces Unaudited Group and Parent Company Earnings Results for the Second Quarter and Six Months Ended December 31, 2017	18-02-08	CI
Nuevolution AB Appoints Dr. Paul Scigalla as Chief Medical Officer on Consultancy Basis	18-01-23	CI
Nuevolution AB to Receive License Fee Payment of USD 750,000	18-01-03	CI
Nuevolution AB elects Fredrik Arp as New Member of the Board	17-12-11	CI
Nuevolution AB Reports Unaudited Consolidated and Parent Earnings Results for the First Quarter Ended September 30, 2017	17-11-06	CI
Nuevolution AB Announces Change of Fiscal Year from 1 July to 30 June to 1 January to 31 December	17-11-06	CI
Nuevolution AB Appoints Johnny Stilou as Director of Investor Relations & Corporate Communication	17-11-03	CI

Chart Nuevolution AB (publ)

Duration

Period

More charts

Company Profile

Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Companyâs business is conducted through its wholly owned subsidiary, Nuevolution A/S.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
NUEVOLUTION AB (PUBL)	+90.59%	0
CSL LIMITED	-2.32%	92.59B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.43B
BIOGEN INC.	-10.90%	33.49B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.62B
INCYTE CORPORATION	-9.06%	12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.35B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.97B
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B

Biopharmaceuticals

Nuevolution AB (publ)

Equities

NUE

SE0007730650

Pharmaceuticals

Nuevolution A/S Appoints Zambrowicz as Director and Senior Scientific Advisor to the Board of Directors

Latest news about Nuevolution AB (publ)

Chart Nuevolution AB (publ)

Company Profile

Sector Biopharmaceuticals